Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
National Dental Pulp Laboratory (NDPL) is a biotechnology company specializing in the cryopreservation and banking of dental pulp stem cells. The company provides a specialized service for the collection, processing, and long-term storage of mesenchymal stem cells (MSCs) derived from exfoliated deciduous teeth (baby teeth) and extracted third molars (wisdom teeth). These banked cells are intended for potential future use in regenerative medicine and personalized cellular therapies to treat various diseases or injuries. NDPL operates an FDA-registered laboratory facility and collaborates with dental professionals to facilitate the recovery process during routine dental procedures. The company's business model focuses on providing families with a biological insurance option by securing high-quality stem cells at a young age.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on National Dental Pulp Laboratory.